41 – 50 of 72
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden
(
- Contribution to journal › Article
-
Mark
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
(
- Contribution to journal › Article
-
Mark
Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma
(
- Contribution to journal › Article
- 2015
-
Mark
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
(
- Contribution to journal › Article
-
Mark
Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.
(
- Contribution to journal › Article
-
Mark
A phase 1 dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma.
(
- Contribution to journal › Article
-
Mark
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Genetic and epigenetic characterization of hypodiploid acute lymphoblastic leukemia.
(
- Contribution to journal › Article
- 2014
-
Mark
Low production of reactive oxygen species in granulocytes is associated with organ damage in systemic lupus erythematosus
(
- Contribution to journal › Article
-
Mark
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.
(
- Contribution to journal › Scientific review